Acta Pharmaceuticals raises $24m for Alzheimer’s therapies

Acta Pharmaceuticals has secured $24m in seed funding for advancing a drug pipeline focused on early intervention and prevention of AD, including the clinical progression of its lead candidate, GSM-779690T. Acta Pharmaceuticals expects to begin a Phase I clinical trial in October 2026 for its lead asset, GSM-779690T. Researchers will examine the oral small-molecule GSM-779690T ‘s tolerability, pharmacokinetics, and safety. Credit: Gorodenkoff/Shutterstock.com. Acta Pharmaceuticals has secured $24m in seed funding for advancing a drug pipeline focused on early intervention and prevention of Alzheimer’s disease (AD), including the clinical progression of its lead candidate, GSM-779690T. It is a gamma-secretase modulator being…

Source: Pharmaceutical Technology